Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2),...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Brandão, Leonardo R., Albisetti, Manuela, Halton, Jacqueline, Bomgaars, Lisa, Chalmers, Elizabeth, Mitchell, Lesley G., Nurmeev, Ildar, Svirin, Pavel, Kuhn, Tomas, Zapletal, Ondrej, Tartakovsky, Igor, Simetzberger, Monika, Huang, Fenglei, Sun, Zhichao, Kreuzer, Jörg, Gropper, Savion, Brueckmann, Martina, Luciani, Matteo
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019192/
https://ncbi.nlm.nih.gov/pubmed/31805182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000998
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars